Prostatype Genomics enters German market

Report this content

Prostatype Genomics can today announce its expansion into Germany, a key priority for the Company. Starting immediately, Karlheinz Dewald will represent the company and the Prostatype® prostate cancer test on the German market.

Prostatype Genomics CEO, Fredrik Persson, comments: “I am very happy about entering the German market. This is a key milestone in Prostatype Genomics commercial plan, and we have been meticulous in finding the right partner to execute the Prostatype® launch in Germany. Karlheinz Dewald´s organization has the expertise and experience to represent innovative products, and we are convinced this is the right way to establish Prostatype® in Germany.”

Fredrik Persson

Media enquiries

Certified Advisor

Svensk Kapitalmarknadsgranskning AB, 011-32 30 732,

Prostatype® is a genetic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or non-treatment of prostate cancer. The test was developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.


Documents & Links